Drug
Treprostinil Palmitil Inhalation
Treprostinil Palmitil Inhalation: highest development phase Phase 3, developed by Insmed. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Insmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Treprostinil Palmitil Inhalation Powder NCT07179380 | Phase 3 | Pulmonary Hypertension |
| Treprostinil Palmitil Inhalation Powder NCT07481981 | Phase 3 | Pulmonary Arterial Hypertension |
| Treprostinil Palmitil Inhalation Powder NCT07805785 | Phase 3 | Progressive Pulmonary Fibrosis |
| Treprostinil Palmitil Inhalation Powder NCT07234032 | Phase 3 | Pulmonary Hypertension |
| Treprostinil Palmitil Inhalation Powder NCT05649722 | Phase 2/3 | Pulmonary Hypertension |
| Treprostinil Palmitil Inhalation Powder NCT06091579 | Phase 1 | Healthy Volunteers |
| Treprostinil Palmitil Inhalation Powder NCT07643155 | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Treprostinil Palmitil Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.